Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | AGER | Q15109 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9339156 | 0.90 | KDM4E (0.44) | KDM4EMAPTCYP1A2HRH1MKNK1 | |
| SCHEMBL3673649 | 0.86 | KDM4E (0.46) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL4030545 | 0.85 | KDM4E (0.49) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL3716799 | 0.84 | KDM4E (0.45) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL28252084 | 0.84 | KDM4E (0.45) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL28001171 | 0.83 | KDM4E (0.50) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL2516051 | 0.81 | KDM4E (0.49) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL1503132 | 0.81 | KDM4E (0.49) | KDM4EMAPTCYP1A2MKNK1MKNK2 | |
| SCHEMBL11182436 | 0.81 | KDM4E (0.47) | KDM4EMAPTCYP1A2ALDH1A1TSHR | |
| SCHEMBL11042558 | 0.81 | KDM4E (0.43) | KDM4EMAPTCYP1A2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312316-A1 | NOVEL COMPOUNDS | BIOTICA TECHNOLOGY LIMITED (GB) | 2009-12-17 | — | — | US | claimed |
| EP-2023915-A2 | BORRELIDIN DERIVATIVES AS ANTIPROLIFERATIVE AGENTS AND ANGIOGENESIS INHIBITORS | Biotica Technology Limited (GB) | 2009-02-18 | — | — | EP | claimed |
| WO-2007135078-A2 | BORRELIDIN DERIVATIVES AS ANTIPROLIFERATIVE AGENTS AND ANGIOGENESIS INHIBITORS | BIOTICA TECHNOLOGY LIMITED (GB) | 2007-11-29 | — | — | WO | claimed |
| EP-0644772-A4 | OPIOID PEPTIDES. | BIOMEASURE INC (US) | 1997-01-29 | — | — | EP | claimed |
| EP-0644772-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1995-03-29 | — | — | EP | claimed |
| WO-1994011018-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1994-05-26 | — | — | WO | claimed |
| US-20090312316-A1 | NOVEL COMPOUNDS | BIOTICA TECHNOLOGY LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| EP-2023915-A2 | BORRELIDIN DERIVATIVES AS ANTIPROLIFERATIVE AGENTS AND ANGIOGENESIS INHIBITORS | Biotica Technology Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135078-A2 | BORRELIDIN DERIVATIVES AS ANTIPROLIFERATIVE AGENTS AND ANGIOGENESIS INHIBITORS | BIOTICA TECHNOLOGY LIMITED (GB) | 2007-11-29 | — | — | WO | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-0644772-B1 | OPIOID PEPTIDES | SOD CONSEILS RECH APPLIC (FR) | 2003-04-02 | — | — | EP | disclosed |
| US-5663295-A | ANALGESIC, ANTIDIARRHEA | BIOMEASURE INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0644772-A4 | OPIOID PEPTIDES. | BIOMEASURE INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0644772-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994011018-A1 | OPIOID PEPTIDES | BIOMEASURE, INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0556738-A1 | Pyridinylcarbonylaminoalkyl-dihydro-oxo-pyridines, their production and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312316-A1 | NOVEL COMPOUNDS | CD22, ALDH1A2, BCAP31 | KDM4E 3837/4885MAPT 3645/4885CYP1A2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.